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Abstract
Mitochondrial dysfunction due to impaired respiratory chain function is increasingly recognized as an important cause of human disease.
Mitochondrial disorders are relatively common and have an estimated incidence of 1:10,000 live births. There are more than 100 different
point mutations and numerous large rearrangements of mitochondrial DNA (mtDNA; mainly single deletions) that cause human disease. We
aimed at obtaining an animal model to study physiological aspects of mtDNA mutation disorders. There are as yet unsolved technical
problems associated with transfection of mammalian mitochondria. We therefore choose to manipulate mtDNA expression by targeting of the
nuclear gene encoding Tfam. We utilised the cre-loxP recombination system to disrupt Tfam since this system allows manipulation of
respiratory chain function in selected mouse tissues. We have found increased cell death or apoptosis induction in both germ line and tissue-
specific Tfam knockouts. Our results further suggest that increased production of reactive oxygen species (ROS) is not a prominent feature in
cells with impaired mtDNA expression.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Mitochondrial dysfunction in human pathology
Mitochondrial dysfunction due to impaired respiratory
chain function is increasingly recognized as an important
cause of human disease. Most of the 80–100 protein
subunits of the respiratory chain are encoded by the nuclear
genome, whereas only 13 subunits are encoded by mito-
chondrial DNA (mtDNA) [1]. This unique dependence on
two genomes predict that both nuclear and mtDNA muta-
tions directly may interfere with mitochondrial function.
Mitochondrial disorders are relatively common and have an
estimated incidence of 1:10,000 live births [2]. Different
types of mutations in both the nuclear and the mitochondrial
genome have been documented in affected patients. There
are more than 100 different point mutations and numerous
large rearrangements of mtDNA (mainly single deletions)
that cause human disease. Nuclear mutations may involve
genes that encode respiratory chain subunits, assembly
factors for respiratory chain enzyme complexes or proteins
regulating the stability and expression of mtDNA.
In addition to these clearly defined genetic disorders,
there is growing evidence for the involvement of mitochon-
drial dysfunction in common disorders such as neurodegen-
eration (Parkinson and Alzheimer diseases), diabetes
mellitus and heart failure [3,4]. There are also reports
suggesting that an acquired age-dependent accumulation
of somatic mtDNA deletions may contribute to aging
[5,6]. The pathogenic mechanisms by which respiratory
chain deficiencies cause disease are not well understood.
One phenomenon that may contribute to the pathology of
respiratory chain disorders is the irreversible loss of post-
mitotic cells such as neurons and cardiomyocytes.
2. The enzymatic machinery for mammalian mtDNA
transcription
The mammalian mtDNA is a small circular molecule of
f 16 kb with a very compact organization of intron-less
genes. There is only one longer non-coding region contain-
ing the control elements for transcription and replication of
mtDNA. Mammalian mtDNA only contains two major
promoters, the light- and heavy-strand promoters (LSP
and HSP), which produce near-genomic length transcripts
that after RNA processing release individual mRNAs,
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tRNAs and rRNAs [7,8]. There is likely a separate tran-
scription unit for the rRNA genes in mammalian mitochon-
dria, which explains why the steady-state levels of rRNAs
are much higher than the steady-state levels of mRNAs.
Both a second HSP dedicated to rRNA gene transcription
[9,10] and a specific transcription terminator binding down-
stream of the rRNA transcription unit have been described
[11–13]. Transcription from LSP is not only necessary for
gene expression but also for production of RNA primers
required for initiation of mtDNA replication.
Human mitochondrial transcription has been reconsti-
tuted in vitro with partially purified enzyme fractions
[14,15]. Mammalian mtDNA transcription is critically
dependent on a high-mobility group-box protein called
mitochondrial transcription factor A (TFAM). Recombinant
TFAM protein and a partially purified mtRNAP fraction
are sufficient for activation of human mtDNA transcription
from LSP and HSP in vitro [14,16,17]. However, experi-
ments aimed at in vitro reconstitution of human mtDNA
transcription with recombinant mtRNAP and TFAM pro-
teins have been unsuccessful and it has been speculated
that additional factors are required [18]. An activity that
co-purifies with a 40-kDa protein and which stimulates
transcription by interacting with the mtRNAP has been
described in Xenopus laevis [19,20], but the corresponding
gene has not been cloned in mammals.
The budding yeast, Saccharomyces cerevisiae, has been
touted as a model system for mammalian mtDNA tran-
scription but several fundamental differences between yeast
and mammals have limited its usefulness. The mtDNA of S.
cerevisiae is large (f 86 kb) and has a complex organiza-
tion with abundant non-coding regions and genes interrup-
ted by introns. Futhermore, initiation of transcription of S.
cerevisiae mtDNA occurs from several simple promoters
and is critically dependent on only two proteins, the yeast
mitochondrial RNA polymerase (Rpo41) and its specificity
factor (Mtf1, also called mitochondrial transcription factor
B). Surprisingly, the yeast TFAM homologue, Abf2, does
not activate transcription but rather functions as an mtDNA
stability factor [17,21]. Another important difference is that
specific mechanisms for termination of mtDNA transcrip-
tion, which have a key regulatory role in metazoans [22,23],
have not been found in yeast. It is thus possible that the
evolution of multicellular organisms with specialized cell
types has necessitated the development of more complex
regulation of mtDNA transcription. In-depth understanding
of mammalian physiology will therefore require definition
of the basal enzymatic machinery for mammalian mtDNA
transcription and understanding of its regulation.
3. Manipulation of mitochondrial transcription factor A
(Tfam) expression in the mouse
There are as yet unsolved technical problems associated
with transfection of mammalian mitochondria and we there-
fore choose to manipulate mtDNA expression by targeting
of the nuclear gene encoding Tfam. We utilised the cre-loxP
recombination system to disrupt Tfam since this system
allows manipulation of respiratory chain function in selected
mouse tissues (Fig. 1). The cre-loxP recombination techni-
que involves two distinct steps; introduction of loxP sequen-
ces in the targeted locus and subsequent deletion of the
sequences flanked by loxP sites mediated by expression of
cre-recombinase. We performed homologous recombination
in embryonic stem (ES) cells and subsequently generated
mice with loxP sequences flanking exons 6 and 7 of the
Tfam gene (TfamloxP). Insertion of loxP sites into the Tfam
locus does not impair the expression of Tfam protein,
mtDNA expression or the respiratory chain function and
mice homozygous for this allele (TfamloxP/TfamloxP) are
normal. The excision of exons 6 and 7 of Tfam was
accomplished by DNA recombination between the two loxP
sites when TfamloxP mice were mated with transgenic mice
Fig. 1. The principle for cre-loxP-mediated disruption of Tfam. The wild-type Tfam locus, the Tfam locus with inserted loxP sites (TfamloxP locus) and the
knockout locus (Tfam locus) are shown. Mice with the TfamloxP locus can be mated with mice that express cre-recombinase to obtain germ line Tfam
knockouts (ubiquitous cre expression) or cell-type specific Tfam knockouts (tissue-specific cre expression).
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expressing cre-recombinase. We have recently reviewed
technical aspects on the generation, breeding and character-
ization of TfamloxP mice [24,25].
Initially, germ line Tfam knockouts were generated by
mating heterozygous TfamloxP mice (+/TfamloxP) with ani-
mals ubiquitously expressing cre-recombinase in the pre-
implantation embryo (b-actin cre; [26]). This mating
generated viable and normally appearing heterozygous Tfam
knockouts (+/Tfam  ). Interestingly, the +/Tfam  mice
exhibited reduced mtDNA copy number (f 30–40%
reduction) in all analysed tissues and reduced activities in
the heart of respiratory chain complexes I, III, IV and V, all
of which contain mtDNA-encoded subunits. Surprisingly,
the levels of mitochondrial transcripts and mtDNA-encoded
respiratory chain subunits were normal in most tissues
despite the general reduction of mtDNA copy number. It
is likely that a compensatory increased stability of mito-
chondrial transcripts and proteins explains this phenom-
enon.
Homozygous knockouts were obtained by an intercross
of +/Tfam  mice and we could determine that loss of Tfam
was embryonic lethal between embryonic day (E) 8.5 and
E10.5. Homozygous-knockout (Tfam  /Tfam  ) embryos
had a mutant phenotype with delayed neural development
and absence of cardiac structures at E8.5. The Tfam  /
Tfam  embryos completely lacked Tfam protein and con-
tained no or extremely low levels of mtDNA. Tfam is thus
essential for mtDNA maintenance in vivo and loss of Tfam
is not compatible with normal embryonic development.
4. Tissue-specific disruption of Tfam in the mouse
The generation of mice with germ-line disruption of
Tfam demonstrated that the cre-loxP-mediated recombina-
tion worked efficiently in vivo and we therefore could
proceed with generating a series of tissue-specific Tfam-
knockout mice by mating TfamloxP mice to a variety of
transgenic mice with cell-type-specific expression of cre-
recombinase [27–30]. Disruption of mtDNA expression in
cardiomyocytes, pancreatic h-cells and cortical neurons
generated animal models for mitochondrial cardiomyopathy,
mitochondrial diabetes and mitochondrial neurodegenera-
tion. The animal models reproduced important aspects of
human mitochondrial disease and also gave novel insight
into key pathophysiological events. Tissue-specific disrup-
tion of Tfam in cardiomyocytes resulted in dilated cardio-
myopathy with atrioventricular heart conduction blocks
[27,28]. Inactivation of Tfam in h-cells resulted in impaired
stimulus-secretion coupling, that is, inability of the h-cell to
release insulin in response to glucose challenge, followed by
h-cell death in older knockouts [29]. Disruption of Tfam in
cortical neurons resulted in increased neuronal stress sensi-
tivity and massive neurodegeneration [30].
Interestingly, the different tissue-specific Tfam knock-
outs have several important features in common. (i) There
is always a time lag between the onset of cre expression
(resulting in disruption of the Tfam gene) and the occur-
rence of severe respiratory chain deficiency. This time lag
is 1–3 weeks in cardiomyocytes and h-cells and 2–3
months in cortical neurons. It is likely that the period
between Tfam knockout and onset of respiratory chain
deficiency is determined by turnover rates for Tfam tran-
scripts, Tfam protein, mtDNA, mitochondrial transcripts
and mtDNA-encoded respiratory chain subunits. Previous
studies have shown that inhibition of mtDNA expression
in cell lines may dramatically increase the stability of
mtDNA-encoded transcripts and proteins [31]. We find it
likely that similar mechanisms operate in real tissues and
that tissue-specific differences in these compensatory
responses are of importance for determining the time point
for onset of respiratory chain disease. (ii) There is a
parallel decline of mtDNA levels and mitochondrial
RNA levels in tissues with homozygous Tfam knockout.
This indicates that there is a rather strong coupling
between mtDNA transcription and mtDNA replication in
a variety of cell types. (iii) There is always a lag phase
between the onset of severe respiratory chain disease and
cell death. The most striking example so far is cortical
neurons which remain viable for at least 1 month despite
severe respiratory chain deficiency. We think that factors
such as compensatory ATP production from glycolysis and
nutrient supply from other cell types (e.g. glial cells) may
determine the viability of Tfam-knockout cells.
5. Cell death is a prominent feature in severe respiratory
chain disease
Apoptosis is a physiological process important for main-
tenance of tissue homeostasis and development and it is also a
physiologic response of the cell after exposure to pathologic
stimuli. Its execution requires energy and involves activation
of specific pathways. Apoptosis is characterized by a number
of morphological hallmarks, for example, cell shrinkage,
membrane blebbing, nuclear condensation, and DNA frag-
mentation. The apoptotic cell is fragmented and phagocy-
tosed by neighbouring cells in vivo without causing an
inflammatory reaction or a scar formation in the tissue. In
contrast to apoptosis, necrosis is a passive process charac-
terized by cell lysis, resulting in tissue damage, followed by
an inflammatory reaction and scar formation. Mitochondria
have been ascribed a role in apoptosis induction as they
release a variety of pro-apoptotic factors. This leads to the
question whether respiratory chain deficiency sensitizes the
release of these factors under different physiological, tissue-
dependent conditions. Mitochondria have a central role in
programmed cell death, apoptosis, and may induce apoptosis
by releasing apoptosis-inducing factors from the intermem-
brane space to the cytosol. This initiates a cascade of events
which activates caspase 3 and results in DNA fragmentation.
Studies of cell lines with respiratory chain dysfunction have
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shown that mtDNA is not required for induction of apoptosis
signalling. We and others have found that human mtDNA-
less (U0) cell lines are susceptible to apoptosis induction in
vitro by a variety of different stimuli [32]. It is interesting to
note that cell death is a prominent feature of at least some
human mitochondrial disorders. Infants with the genetically
heterogeneous Leigh syndrome display a massive cell death
in the brain stem [33] and patients with mitochondrial
diabetes display a marked loss of h-cells [34,35].
We have found evidence for increased cell death due to
apoptosis induction in both germ line and tissue-specific
Tfam knockouts (Fig. 2). We found that mouse embryos
with homozygous Tfam knockout were viable with a mutant
phenotype at E8.5 and displayed a massive increase of
TUNEL reactive cells and activation of caspase 3 at E9.5
followed by embryo resorption at E10.5 [32]. Mouse hearts
with tissue-specific disruption of Tfam display increased
numbers of cardiomyocytes that are TUNEL positive and
express activated caspase 3 and activated caspase 7. Apop-
tosis could also be confirmed by visualizing DNA fragmen-
tation on agarose gels containing DNA from Tfam-knockout
hearts [32].
The h-cell-specific Tfam-knockout animals are diabetic
and display viable but malfunctioning h-cells that cannot
release insulin when stimulated by glucose. A significant
loss of the respiratory chain-deficient h-cells occurs in the
older knockout animals. The absence of islet inflammation
in these animals suggests an apoptotic cell death but
expression of specific apoptosis markers was not found [29].
Disruption of Tfam in cortical neurons causes a massive
neurodegeneration with abundant TUNEL positive neurons
in neocortex and hippocampus [30]. DNA fragmentation is
Fig. 2. Cell death is a prominent feature in different cell types with disruption of mtDNA expression. (A) Staining to detect TUNEL reactivity and activated
caspase 3 in tissue sections from homozygous Tfam-knockout and control embryos at embryonic day (E) 9.5. Massive amounts of TUNEL positive cells and
strong expression of activated caspase 3 are seen in the Tfam-knockout embryos. (B) Staining to detect TUNEL reactivity and activated caspase 3 in tissue
sections from Tfam-knockout and control hearts. Increased amounts of TUNEL positive cells and increased expression of activated caspase 3 are seen in the
Tfam-knockout hearts. (C) Staining to detect TUNEL reactivity and morphology in brain sections from mice with Tfam-knockout cortical neurons and control
mice. A massive increase of TUNEL positive cells and disruption of cortical layering are seen in the mice with Tfam-knockout neurons. (D) Staining to detect
insulin expression in islets with Tfam-knockout h-cells and control islets. A severe reduction of h-cells expressing insulin (brown immunoreactive material) is
seen in the Tfam-knockout islet.
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detectable by PCR analysis of DNA from cortex. Surpris-
ingly, these neurons do not express activated caspase 3 or
activated caspase 7 despite the massive amount of cell
death. The severely respiratory chain-deficient neurons are
present at least 1 month before onset of neurodegeneration.
Interestingly, the respiratory chain-deficient neurons are
more prone to excitotoxic cell death (e.g. after kainate-
induced seizures) than normal neurons.
In conclusion, both embryonic and terminally differ-
entiated cells with mtDNA depletion and respiratory chain
deficiency are more prone to apoptosis in vivo than normal
cells. It is possible that increased production of reactive
oxygen species (ROS) is of importance for apoptosis induc-
tion in mtDNA-depleted cells but there is no strong evi-
dence for this. The respiratory chain-deficient hearts
displayed moderately increased levels of glutathione perox-
idase (Gpx) and mitochondrial superoxide dismutase (Sod2)
transcripts and increased Gpx enzyme activity, but we could
not detect any reduction in the activity of the ROS-sensitive
iron–sulphur cluster containing enzymes aconitase and
SDH [32]. In contrast, there was no induction of ROS
defences in respiratory chain-deficient neurons despite
much more pronounced cell death [30]. It is possible that
the combined respiratory chain deficiency obtained in
mtDNA-depletion tissues is less prone to increased ROS
production than respiratory chain deficiencies affecting
specific complexes.
We also found increased transcript levels of the glyco-
lytic enzyme glyceraldehyde-3-phosphate dehydrogenase in
Tfam-knockout hearts but not in Tfam-knockout neurons
suggesting that glycolytic ATP production may be of
importance for apoptosis execution in respiratory-deficient
cells. The exact mechanism by which respiratory chain-
deficient cells undergo apoptosis is not clear but it is likely
that the reduced oxidative phosphorylation capacity affects
the mitochondrial membrane potential, perhaps making the
cells more likely to undergo mitochondrial membrane per-
meability transition whereby apoptosis-inducing factors are
released to the cytosol. However, it still remains open if
cytochrome c-mediated apoptosis is the main in vivo path-
way in cells lacking mtDNA or whether other cytochrome c-
independent pathways contribute to the process. Our results
also suggest that there may be tissue-specific pathways for
apoptosis signalling in mitochondrial disease.
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